MedTrace Logo

Sirolimus and Vismodegib in Treating Patients With Solid Tumors or Pancreatic Cancer That is Metastatic or Cannot Be Removed By Surgery

NCT01537107 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 31

Last updated 2019-04-08

No results posted yet for this study

Summary

This phase I trial studies the side effects and the best dose of sirolimus when given together with vismodegib in treating patients with solid tumors or pancreatic cancer that is metastatic or cannot be removed by surgery. Sirolimus and vismodegib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth

Conditions

  • Acinar Cell Adenocarcinoma of the Pancreas
  • Duct Cell Adenocarcinoma of the Pancreas
  • Recurrent Pancreatic Cancer
  • Stage IV Pancreatic Cancer
  • Unspecified Adult Solid Tumor, Protocol Specific

Interventions

DRUG

vismodegib

Given PO

DRUG

sirolimus

Given PO

PROCEDURE

positron emission tomography

Correlative studies

PROCEDURE

computed tomography

Correlative studies

OTHER

pharmacological study

Correlative studies

OTHER

laboratory biomarker analysis

Correlative studies

RADIATION

fludeoxyglucose F 18

Correlative studies

Sponsors & Collaborators

Principal Investigators

  • Charles Erlichman, M.D. · Mayo Clinic

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-03-05
Primary Completion
2018-06-27
Completion
2018-06-27

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01537107 on ClinicalTrials.gov